NIKKEI 225
37,817.66 +189.18 (+0.50%) HANG SENG
17,556.50 +271.96 (+1.57%) CRUDE OIL
83.85 +0.28 (+0.34%) GOLD FUTURES
2,347.70 +5.20 (+0.22%) DOW
38,085.80 -375.12 (-0.98%) Bitcoin GBP
51,500.79 +108.20 (+0.21%)
Cyclacel Pharmaceuticals, Inc. (CYCC)
After hours:
| Previous close | 2.2800 |
| Open | 1.8600 |
| Bid | 1.6600 x 100 |
| Ask | 0.0000 x 0 |
| Day's range | 1.4101 - 1.9872 |
| 52-week range | 1.4100 - 13.2000 |
| Volume | |
| Avg. volume | 109,438 |
| Market cap | 3.032M |
| Beta (5Y monthly) | 0.57 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -18.6100 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 16.00 |
Simply Wall St.Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Is Expected To Breakeven In The Near Future
Cyclacel Pharmaceuticals, Inc. ( NASDAQ:CYCC ) is possibly approaching a major achievement in its business, so we would...
GlobeNewswireCyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer
- New clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing development program in patients with solid tumors and lymphoma - BERKELEY HEIGHTS, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that new clinical, pharmacokinetic (PK) and pharmacodynamic (PD) data fr
Insider MonkeyCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2023 Earnings Call Transcript
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2023 Earnings Call Transcript March 19, 2024 Cyclacel Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-6.23, expectations were $-6.35. CYCC isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon and welcome to the […]
